Mod GRF 5 mg
Main Image

Mod GRF 5 mg

Steroids Dragon Pharma Peptide

$26.40

Mod GRF 5 mg (CJC-1295 without DAC) – Peptide Hubs

Mod GRF 1-29, commonly referred to as CJC-1295 without DAC, is a short-acting growth hormone-releasing hormone (GHRH) analog. It has been modified to enhance stability while avoiding long-term GH elevation, offering a pulsatile GH release pattern more in line with natural secretion. Peptide Hubs supplies Mod GRF in a 5 mg lyophilized vial for scientific research on recovery, GH dynamics, and anti-aging protocols.

Mechanism of Action

Mod GRF acts on the anterior pituitary by stimulating GHRH receptors, promoting a natural pulse of growth hormone. Unlike its long-acting DAC version, it mimics the body's endogenous GH rhythm and is often paired with GHRP compounds like GHRP-2 or Ipamorelin to amplify the GH surge. It avoids constant GH elevation, reducing desensitization risks. For more, see this NIH paper on GHRH analogs.

Research Applications

  • Growth hormone pulse stimulation studies
  • Recovery and injury repair models
  • Anti-aging and cellular rejuvenation research
  • GH axis modulation and endocrine function experiments

Mod GRF is often used in conjunction with GHRP-6 or GHRP-2 for synergistic GH release. It may also be stacked with GHK Basic for tissue recovery or AOD 9604 for metabolic studies.

Dispatched within 24 hours in plain, discreet packaging.

Additional Information

Categories:
Brand: Dragon Pharma
Manufacturer: Dragon Pharma
Dosage Info: <div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel"> <section class="tab-panel" id="panel-usage"> <h2>Dosage &amp; Usage Guidelines</h2> <ul> <li><strong>Dosage:</strong> 100–200 mcg per injection, 2–3 times daily</li> <li><strong>Administration:</strong> Subcutaneous injection, often timed with GHRP administration</li> <li><strong>Cycle Duration:</strong> 4–12 weeks in GH restoration protocols</li> </ul> <h3>Stacking Recommendations</h3> <ul> <li><strong>GHRP-2</strong> – for amplified GH surge and pituitary stimulation</li> <li>DSIP – for sleep-dependent GH optimization and recovery</li> <li><strong>GHK Basic</strong> – to support collagen synthesis and injury repair</li> <li>Semaglutide – in metabolic modulation and fat-loss studies</li> </ul> <h3>Safety &amp; Legal Status</h3> <p>Mod GRF is sold strictly for <strong>laboratory research use only</strong> and is not FDA-approved. It has shown excellent tolerability with no aromatization, hepatotoxicity, or suppression of endogenous hormones. For trial listings, visit <a href="https://clinicaltrials.gov/" rel="noopener" target="_blank">ClinicalTrials.gov</a>.</p> </section> </div>
Reviews:
(0 customer reviews)

Technical Details

Peptide Type
Modified GHRH Analogue
Peptide Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Peptide Length
29 Amino-Acid Residues
Structural Origin
Human GHRH(1-29) Analogue
Sequence Modifications
D-Ala² · Gln⁸ · Ala¹⁵ · Leu²⁷
Terminal Form
C-Terminal Amide (-NH₂)
Molecular Formula
C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight
3367.9 g/mol
PubChem CID
91976842
Receptor Target
GHRH Receptor (GHRHR)
DAC Modification
None
Research Status
Experimental / Research Compound

Chat on WhatsApp